NetraMark Holdings Inc.

AIAI

CA64119M1059

Software

Market Closed - Canadian Securities Exchange Other stock markets 12:15:27 18/07/2024 am IST			5-day change	1st Jan Change
0.26 ^CAD	-1.89%		-8.77%	-25.71%

10/06	NetraMark Holdings Inc. Announces Collaboration Agreement with National Institute of Mental Health to Analyze Clinical Trial Data on the Use of Ketamine in Mental Disorders	CI
09/06	257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	CI

Nurosene Health Inc. Reports Earnings Results for the Full Year Ended September 30, 2022

January 27, 2023

Nurosene Health Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported sales was CAD 0.113031 million. Revenue was CAD 0.113031 million.

Net loss was CAD 13.45 million compared to CAD 5.08 million a year ago. Basic loss per share from continuing operations was CAD 0.33 compared to CAD 0.2 a year ago.

Latest news about NetraMark Holdings Inc.

NetraMark Holdings Inc. Announces Collaboration Agreement with National Institute of Mental Health to Analyze Clinical Trial Data on the Use of Ketamine in Mental Disorders	10/06	CI
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06	CI
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06	CI
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14/05	CI
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	10/04	CI
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	04/04	CI
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	12/03	CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	11/03	MT
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	11/03	CI
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	27/02	CI
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	27/02	CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients	26/02	CI
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials	15/02	CI
NetraMark Holdings Inc. Announces Launch of the NetraAI Lab Offering	12/02	CI
NetraMark Up 8.6% After Reporting Third Contract With Biopharmaceutical Firm	30/01	MT
Netramark Holdings Inc. Signs Third Contract with Biopharmaceutical Company	30/01	CI
NetraMark Holdings Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	27/01	CI
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates	16/01	CI
NetraMark Holdings Inc. Signs Two Contracts with Large Biopharmaceutical Company to Enhance Clinical Trial Insights	20/12	CI
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023.	09/12	CI
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2023.	09/12	CI
NetraMark Holdings Inc. Announces Management Changes	06/11	CI
NetraMark Holdings Inc. Signs Master Service Agreement with Large Biopharmaceutical Company	31/23/31	CI
NetraMark Holdings Inc. announced that it has received CAD 2 million in funding	19/23/19	CI
NetraMark Holdings Inc. announced that it expects to receive CAD 1.5 million in funding	11/23/11	CI

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Companyâs product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.

Sector

Software

Calendar

26/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Software

	1st Jan change	Capi.
NETRAMARK HOLDINGS INC.	-25.71%	13.41M
MICROSOFT CORPORATION	+17.94%	3,341B
SYNOPSYS INC.	+10.77%	93.92B
CADENCE DESIGN SYSTEMS, INC.	+5.78%	85.47B
PALANTIR TECHNOLOGIES INC.	+64.36%	63.85B
THE TRADE DESK, INC.	+32.35%	49.38B
DASSAULT SYSTÈMES SE	-22.66%	48.74B
ATLASSIAN CORPORATION	-24.78%	47.68B
SEA LIMITED	+71.95%	40.9B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-6.88%	26.97B